Healthcare Business Recap: Boston Scientific’s Good News, Cell Therapeutics Pops
Boston Scientific’s (NYSE:BSX) current acquisition, Cameron Health, reports that its implantable heart defibrillator was safe and effective in a trial involving 330 patients. This device is the pioneer model in which wires are unnecessary for transmission of electricity to the heart and thus will eliminate complications that the leads cause.
Shares of Quality Systems (NASDAQ:QSII) fall following an early Thursday warning that its fiscal fourth quarter numbers will miss consensus. CEO Steven Plochocki blames delays connected to both the closing of several “opportunities” to the healthcare information tech company, and revenue recognition on a large project.
Cell Therapeutics (NASDAQ:CTIC) shares pop following the news that CTIC’s Pixuvri cancer drug is approved in the European Union as monotherapy to treat adults with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. The drug is the first to be approved there in this patient setting.
Trading of Arena Pharmaceutical (NASDAQ:ARNA) is halted after hours, as the FDA votes 18 to 4 to 1 to move the firm’s weight loss drug lorcaserin to regulators for approval or rejection. Stocks of other drug firms Orexigen Therapeutics (NASDAQ:OREX), and Vivus Inc. (NASDAQ:VVUS) move up in sympathy.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.
Don’t Miss: Can Berkshire Make a Buyout Sexy for Avon?